Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.38 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9404780 | 0.82 | MCHR1 (0.45) | MEN1KMT2ATSHRNCF1 | |
| SCHEMBL9404769 | 0.73 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2298646 | 0.73 | TIPARP (0.41) | KDM1ATIPARPALDH1A1GRM7SCN9A | |
| SCHEMBL18574221 | 0.72 | HTR1B (0.47) | KDM1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL301029 | 0.70 | NPC1 (0.41) | — | |
| SCHEMBL2974587 | 0.69 | MAPT (0.56) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4976411 | 0.69 | SRC (0.44) | TIPARPGRM7EGFR | |
| SCHEMBL23352277 | 0.68 | CYP1A2 (0.44) | KDM1ANCF1SMN1; SMN2 | |
| SCHEMBL14861020 | 0.68 | HTR2C (0.42) | KDM1ATIPARPALDH1A1GRM7TSHR | |
| SCHEMBL18561728 | 0.67 | SMN1; SMN2 (0.48) | KDM1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE5A, PDE7A | KDM1A 1058/4885TIPARP 1930/4885ALDH1A1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.